Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 17

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 17
---
 2025 Appointed in Dec - 2021 Appointed in Jul - 2010 Appointed in Jul - 2020 Appointed in Nov - 2009 Appointed in Dec - 2019 22 | Nominating and Corporate Governance Committee Audit Committee Chair* Chair* Chair * Committee appointment to be effective following Annual Meeting. * Board Highlights

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Scott Myers (Chairman) Ryan Spencer (CEO) Francis Cano Emilio Emini Daniel Kisner Brent MacGregor Peter Paradiso Lauren Silvernail Elaine Sun Total Extensive Industry Knowledge P P P P P P P P P 9 / 9 Vaccine Experience (R&D, Sales, Marketing) P P P P P P P 7 / 9 Operational / Commercial Experience P P P P P P P P P 9 / 9 Clinical Development P P P P P 5 / 9 Business Development / M&A Experience P P P P P P P P 8 / 9 Finance/Capital Allocation P P P P P P P P 8 / 9 Public Company C - Suite Experience P P P P P P 6 / 9 Public Health/Government P P 2 / 9 Other Public Company Board Experience P P P P P P 6 / 9 …With the Right Skills and Experiences to Continue Driving Long - Term Value for All Stockholders © Copyright DYNAVAX 2025 23 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Lauren Silvernail Independent Director Elaine Sun Independent Director Brent MacGregor Independent Director Scott Myers Independent Chair Replacing Any of Our Directors With Deep Track Nominees Would Remove Vital Expertise from Our Board 24 | Mr. Myers brings over three decades of expertise in the global pharmaceutical and medical technology industries as a life sciences executive and Board chairperson Ms. Sun brings significant corporate finance, M&A and capital markets expertise in life sciences, enhancing our Board’s oversight of financial and business development matters Mr.